Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Leerink Global Healthcare Conference Transcript

Feb 27, 2020 / 02:00PM GMT
Release Date Price: R$19.69 (-5.44%)
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst

Let's get started with the first company this morning. I'm delighted to welcome Eli Lilly to the Global Healthcare Conference. Kicking stuff for us, they are represented by Patrik Jonsson, President of U.S. Biopharma; and Mike Czapar, Director of Investor Relations. Thank you, gentlemen, for joining us.

Patrik Jonsson
Eli Lilly and Company - Senior VP & President of Lilly Bio-Medicines

Thank you very much.

Questions & Answers

Geoffrey Craig Porges;Patrik Jonsson
SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst

So first of all, obviously, let's talk about psoriasis. How do you think that your psoriasis franchise is going to bear up with all of the recent entrants in multiple IL-23s, more in the pipeline? How big can this category grow? And can you continue to grow your product there?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot